Search Results 1991-2000 of 15558 for Epilepsy (Partial Onset)

1. Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas - Mayo Clinic

   Histologically confirmed relapsed (response to last treatment ≥ 6 months duration) or refractory (no response to last treatment or response duration < 6 months) ...

2. A Study of the Effectiveness of LY3314814 in Patients with Mild Alzheimer's Disease Dementia - Mayo Clinic

   Participation eligibility · Other dementias · Repetitive head trauma · Serious infection of the brain · Parkinson's disease · Epilepsy · Cervicocranial vascular ...

3. A Study of Deep Phenotyping in Patients With ALS - Mayo Clinic

   ... epilepsy. Dental fillings are permitted. Additional criteria for sites performing MRI cytography: Subjects who have a history of claustrophobia that cannot ...

4. Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy - Mayo Clinic

   Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron hydrochloride, may help lessen or prevent nausea and vomiting in patients ...

5. Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia - Mayo Clinic

   ... duration of their participation in the study and for 30 days after the last dose of venetoclax; should a woman become pregnant or suspect she is pregnant ...

6. A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer - Mayo Clinic

   Encephalitis, meningitis, or uncontrolled seizures in the year prior to randomization. History of interstitial lung disease (eg, idiopathic pulmonary ...

7. A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer - Mayo Clinic

   This is a two arm Phase III trial in first and second-line HER2 negative patients with locally recurrent or metastatic breast cancer. The primary endpoint is ...

8. A Study to Evaluate the Use of a Novel Wearable Device for Temperature Monitoring in Cancer Patients Who Underwent Autologous Stem Cell Transplant - Mayo Clinic

   ... duration of the study; Subjects able to record body temperature per the protocol for the duration of the study. Exclusion Criteria: Subjects pregnant or ...

9. S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer - Mayo Clinic

   About this study. RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, ...

10. A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke (REvive) - Mayo Clinic

    Able to initiate study intervention within 25 hours of stroke onset - Determined by the investigator to not be eligible for recanalization thrombolysis or